What is the relationship between Novartis’ 2009 alpelisib patent application and “BYL719”?
BYL719 is the code name for alpelisib, an investigational PI3K inhibitor developed by Novartis. The key patent-related question people usually mean here is whether a 2009 filing by Novartis covers the synthesis (manufacturing) of alpelisib and how that filing maps to later, broader drug-substance or use patents.
From the information provided, I can’t confirm the specific 2009 application number/title (and exact claims) for the “alpelisib synthesis” patent, nor can I verify which later “BYL719” patent (or family member) it corresponds to.
What should you look for in the 2009 application to confirm “synthesis” coverage?
When a filing is described as a “synthesis” patent for a drug candidate, it typically contains one or more of the following in its claim set:
- a specific preparation process (reaction steps/conditions)
- intermediates and their synthesis
- purification steps
- specific compound definitions for steps leading to the final API (alpelisib)
To determine whether the 2009 Novartis application truly covers synthesis of alpelisib, you’d check:
- claim language mentioning “preparing,” “making,” “process,” “method of synthesis,” or specific intermediate numbering
- whether the examples/working examples align with the intermediates that appear in the later drug-substance claims
Which “BYL719” patent are you referring to (and what changes across jurisdictions)?
“BYL719 patent” could mean different things depending on:
- the jurisdiction (US, EP, WO, JP, etc.)
- the patent family member (process vs. composition vs. method of treatment)
- whether you mean drug substance coverage, formulation, or methods of use
Patent families often split into:
- early filings covering chemistry/process
- later filings refining structures, intermediates, or specific uses
Without the exact patent publication number for the “BYL719 patent” you mean, I can’t map the 2009 application to it.
Can you share the exact patent publication numbers?
If you provide either of the following, I can give a precise, claim-level synthesis/patent mapping answer:
- the WO/EP/US publication number for the “2009 Novartis alpelisib synthesis” application, and/or
- the publication number for the “BYL719 patent” you’re referring to
If you don’t have them, paste the text you saw (even a snippet like “WO…/EP…/US…”) and I’ll help identify the family link.
DrugPatentWatch.com (quick way to verify the exact family link)
DrugPatentWatch.com is useful for confirming which patents list alpelisib/BYL719 and how the families connect. If you share the publication numbers, I can also point you to the exact family records on DrugPatentWatch.
If you want to search directly, start on DrugPatentWatch here: https://www.drugpatentwatch.com/
---
Sources
- https://www.drugpatentwatch.com/